CYRX · CryoPort Inc
AI read · Good for CYRX
The AI's read
Commercial cell and gene therapy sales rose 20%, driving much of the growth. The record trial pipeline may support future business if more treatments reach patients. Positive adjusted EBITDA for a second quarter shows progress on operating costs, but this measure excludes some costs and does not establish overall profit.